

Adrian F Ochsenbein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8030246/publications.pdf>

Version: 2024-02-01

101
papers

11,037
citations

53794

45
h-index

34986

98
g-index

103
all docs

103
docs citations

103
times ranked

14709
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. <i>Lancet, The</i> , 2019, 393, 1819-1830.	13.7	2,347
2	Control of Early Viral and Bacterial Distribution and Disease by Natural Antibodies. <i>Science</i> , 1999, 286, 2156-2159.	12.6	822
3	Natural antibodies and complement link innate and acquired immunity. <i>Trends in Immunology</i> , 2000, 21, 624-630.	7.5	479
4	Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. <i>Nature</i> , 2001, 411, 1058-1064.	27.8	469
5	Immune surveillance against a solid tumor fails because of immunological ignorance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999, 96, 2233-2238.	7.1	422
6	Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 2712-2718.	1.6	389
7	FTY720 Immunosuppression Impairs Effector T Cell Peripheral Homing Without Affecting Induction, Expansion, and Memory. <i>Journal of Immunology</i> , 2000, 164, 5761-5770.	0.8	349
8	Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. <i>Lancet, The</i> , 2015, 386, 1049-1056.	13.7	316
9	Immunotherapy with Dendritic Cells Directed against Tumor Antigens Shared with Normal Host Cells Results in Severe Autoimmune Disease. <i>Journal of Experimental Medicine</i> , 2000, 191, 795-804.	8.5	251
10	Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. <i>Blood</i> , 2009, 114, 1528-1536.	1.4	250
11	Microbiota-Derived Compounds Drive Steady-State Granulopoiesis via MyD88/TICAM Signaling. <i>Journal of Immunology</i> , 2014, 193, 5273-5283.	0.8	202
12	Regulation of hematopoietic and leukemic stem cells by the immune system. <i>Cell Death and Differentiation</i> , 2015, 22, 187-198.	11.2	195
13	Protective long-term antibody memory by antigen-driven and T help-dependent differentiation of long-lived memory B cells to short-lived plasma cells independent of secondary lymphoid organs. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 13263-13268.	7.1	187
14	SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer: A Multicenter Single-Arm Phase II Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 2872-2880.	1.6	183
15	Cytotoxic CD8+ T Cells Stimulate Hematopoietic Progenitors by Promoting Cytokine Release from Bone Marrow Mesenchymal Stromal Cells. <i>Cell Stem Cell</i> , 2014, 14, 460-472.	11.1	174
16	Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. <i>Lancet Oncology, The</i> , 2015, 16, 1651-1658.	10.7	170
17	Protective T Cell-Independent Antiviral Antibody Responses Are Dependent on Complement. <i>Journal of Experimental Medicine</i> , 1999, 190, 1165-1174.	8.5	149
18	Viral persistence in vivo through selection of neutralizing antibody-escape variants. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 2749-2754.	7.1	142

#	ARTICLE	IF	CITATIONS
19	CD27 Signaling Increases the Frequency of Regulatory T Cells and Promotes Tumor Growth. <i>Cancer Research</i> , 2012, 72, 3664-3676.	0.9	133
20	IgD can largely substitute for loss of IgM function in B cells. <i>Nature</i> , 1998, 393, 797-801.	27.8	126
21	Targeted Inactivation of the Tetraspanin CD37 Impairs T-Cell-Dependent B-Cell Response under Suboptimal Costimulatory Conditions. <i>Molecular and Cellular Biology</i> , 2000, 20, 5363-5369.	2.3	125
22	CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia. <i>Journal of Experimental Medicine</i> , 2017, 214, 359-380.	8.5	125
23	Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity. <i>Nature Medicine</i> , 2010, 16, 339-345.	30.7	122
24	Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents. <i>Nature Medicine</i> , 2020, 26, 1459-1467.	30.7	122
25	TREM-1 Deficiency Can Attenuate Disease Severity without Affecting Pathogen Clearance. <i>PLoS Pathogens</i> , 2014, 10, e1003900.	4.7	116
26	CD27 Expression Promotes Long-Term Survival of Functional Effectorâ€“Memory CD8+Cytotoxic T Lymphocytes in HIV-infected Patients. <i>Journal of Experimental Medicine</i> , 2004, 200, 1407-1417.	8.5	113
27	Persistence of lymphocytic choriomeningitis virus at very low levels in immune mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999, 96, 11964-11969.	7.1	106
28	Elimination of chronic viral infection by blocking CD27 signaling. <i>Journal of Experimental Medicine</i> , 2006, 203, 2145-2155.	8.5	99
29	Principles of tumor immunosurveillance and implications for immunotherapy. <i>Cancer Gene Therapy</i> , 2002, 9, 1043-1055.	4.6	93
30	Transcapillary escape rate of albumin positively correlates with plasma albumin concentration in acute but not in chronic inflammatory disease. <i>Metabolism: Clinical and Experimental</i> , 1994, 43, 697-705.	3.4	86
31	Role of dendritic cells in the induction and maintenance of autoimmune diseases. <i>Immunological Reviews</i> , 1999, 169, 45-54.	6.0	85
32	Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 381-394.	4.2	84
33	CD27 signaling on chronic myelogenous leukemia stem cells activates Wnt target genes and promotes disease progression. <i>Journal of Clinical Investigation</i> , 2012, 122, 624-638.	8.2	84
34	Rapid Peptide Turnover and Inefficient Presentation of Exogenous Antigen Critically Limit the Activation of Self-Reactive CTL by Dendritic Cells. <i>Journal of Immunology</i> , 2001, 166, 3678-3687.	0.8	82
35	IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasms. <i>Journal of Clinical Investigation</i> , 2015, 125, 2579-2591.	8.2	80
36	Correlation of T Cell Independence of Antibody Responses with Antigen Dose Reaching Secondary Lymphoid Organs: Implications for Splenectomized Patients and Vaccine Design. <i>Journal of Immunology</i> , 2000, 164, 6296-6302.	0.8	76

#	ARTICLE	IF	CITATIONS
37	TREM-1 links dyslipidemia to inflammation and lipid deposition in atherosclerosis. <i>Nature Communications</i> , 2016, 7, 13151.	12.8	76
38	Neutralizing antiviral antibody responses. <i>Advances in Immunology</i> , 2001, 79, 1-53.	2.2	74
39	Cytotoxic T cells induce proliferation of chronic myeloid leukemia stem cells by secreting interferon- γ . <i>Journal of Experimental Medicine</i> , 2013, 210, 605-621.	8.5	72
40	Tyrosine kinase inhibitor-induced CD70 expression mediates drug resistance in leukemia stem cells by activating Wnt signaling. <i>Science Translational Medicine</i> , 2015, 7, 298ra119.	12.4	71
41	CD127+ innate lymphoid cells are dysregulated in treatment naive acute myeloid leukemia patients at diagnosis. <i>Haematologica</i> , 2015, 100, e257-e260.	3.5	69
42	Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections. <i>Blood</i> , 2006, 108, 3406-3413.	1.4	67
43	A comparison of T cell memory against the same antigen induced by virus versus intracellular bacteria. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999, 96, 9293-9298.	7.1	66
44	Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression. <i>Journal of Neuro-Oncology</i> , 2014, 117, 141-145.	2.9	52
45	CD47 protein expression in acute myeloid leukemia: A tissue microarray-based analysis. <i>Leukemia Research</i> , 2015, 39, 749-756.	0.8	48
46	T-cell independent IgM and enduring protective IgG antibodies induced by chimeric measles viruses. <i>Nature Medicine</i> , 1998, 4, 945-948.	30.7	46
47	T-cell-secreted TNF α induces Emergency Myelopoiesis and Myeloid-Derived Suppressor Cell Differentiation in Cancer. <i>Cancer Research</i> , 2019, 79, 346-359.	0.9	45
48	Immunological ignorance of solid tumors. <i>Seminars in Immunopathology</i> , 2005, 27, 19-35.	4.0	44
49	Virus-induced polyclonal B cell activation improves protective CTL memory via retained CD27 expression on memory CTL. <i>European Journal of Immunology</i> , 2005, 35, 3229-3239.	2.9	42
50	CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AML. <i>Blood Advances</i> , 2019, 3, 3674-3687.	5.2	40
51	Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. <i>Acta Oncologica</i> , 2011, 50, 630-635.	1.8	38
52	Tumor Initiation Capacity and Therapy Resistance Are Differential Features of EMT-Related Subpopulations in the NSCLC Cell Line A549. <i>Neoplasia</i> , 2019, 21, 185-196.	5.3	38
53	Natural antibodies target virus-antibody complexes to organized lymphoid tissue. <i>Autoimmunity Reviews</i> , 2008, 7, 480-486.	5.8	37
54	Dendritic Cell-Based Immunotherapy for Myeloid Leukemias. <i>Frontiers in Immunology</i> , 2013, 4, 496.	4.8	37

#	ARTICLE	IF	CITATIONS
55	CD70 reverse signaling enhances NK cell function and immunosurveillance in CD27-expressing B-cell malignancies. <i>Blood</i> , 2017, 130, 297-309.	1.4	37
56	mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer. <i>Oncogene</i> , 2019, 38, 622-636.	5.9	37
57	CD4 ⁺ T cell help improves CD8 ⁺ T cell memory by retained CD27 expression. <i>European Journal of Immunology</i> , 2008, 38, 1847-1856.	2.9	34
58	Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05). <i>Lung Cancer</i> , 2012, 78, 239-244.	2.0	33
59	Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07. <i>Oncology Reports</i> , 2012, 28, 654-658.	2.6	29
60	CD8 ⁺ T cells expand stem and progenitor cells in favorable but not adverse risk acute myeloid leukemia. <i>Leukemia</i> , 2019, 33, 2379-2392.	7.2	29
61	SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC) – A multicenter single-arm phase II trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 9016-9016.	1.6	27
62	Blocking programmed cell death 1 in combination with adoptive cytotoxic T-cell transfer eradicates chronic myelogenous leukemia stem cells. <i>Leukemia</i> , 2015, 29, 1781-1785.	7.2	26
63	Defective homing and impaired induction of cytotoxic T cells by BCR/ABL-expressing dendritic cells. <i>Blood</i> , 2009, 113, 4681-4689.	1.4	24
64	Modulating CD27 signaling to treat cancer. <i>OncImmunology</i> , 2012, 1, 1604-1606.	4.6	24
65	Quantification of fetomaternal hemorrhage by fluorescence microscopy is equivalent to flow cytometry. <i>Transfusion</i> , 2002, 42, 947-953.	1.6	22
66	A prognostic score for non-small cell lung cancer resected after neoadjuvant therapy in comparison with the tumor-node-metastases classification and major pathological response. <i>Modern Pathology</i> , 2021, 34, 1333-1344.	5.5	22
67	Quantitative analysis of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2011, 103, 343-351.	2.9	21
68	Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01). <i>Journal of Thoracic Oncology</i> , 2019, 14, 115-123.	1.1	21
69	Metoclopramide treatment blocks CD93-signaling-mediated self-renewal of chronic myeloid leukemia stem cells. <i>Cell Reports</i> , 2021, 34, 108663.	6.4	21
70	A Btk transgene restores the antiviral TI-2 antibody responses of xid mice in a dose-dependent fashion. <i>European Journal of Immunology</i> , 1999, 29, 2981-2987.	2.9	20
71	Decreased Tumor Surveillance after Adoptive T-Cell Therapy. <i>Cancer Research</i> , 2007, 67, 7467-7476.	0.9	18
72	CTL induction by cross-priming is restricted to immunodominant epitopes. <i>European Journal of Immunology</i> , 2009, 39, 704-716.	2.9	18

#	ARTICLE	IF	CITATIONS
73	Short Peptide Vaccine Induces CD4+ T Helper Cells in Patients with Different Solid Cancers. <i>Cancer Immunology Research</i> , 2016, 4, 18-25.	3.4	18
74	TNIK signaling imprints CD8+ T cell memory formation early after priming. <i>Nature Communications</i> , 2020, 11, 1632.	12.8	16
75	MRI and 18FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial. <i>Clinical Cancer Research</i> , 2021, 27, 179-188.	7.0	16
76	LEFLUNOMIDE-MEDIATED SUPPRESSION OF ANTIVIRAL ANTIBODY AND T CELL RESPONSES: DIFFERENTIAL RESTORATION BY URIDINE1. <i>Transplantation</i> , 2001, 72, 712-719.	1.0	15
77	Destruction of Lymphoid Organ Architecture and Hepatitis Caused by CD4+ T Cells. <i>PLoS ONE</i> , 2011, 6, e24772.	2.5	15
78	A retrospective study of 1- versus 2-cm excision margins for cutaneous malignant melanomas thicker than 2 mm. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 1054-1059.	1.2	15
79	Tnfrsf4-expressing regulatory T cells promote immune escape of chronic myeloid leukemia stem cells. <i>JCI Insight</i> , 2021, 6, .	5.0	15
80	Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Nonâ€“Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09. <i>Clinical Lung Cancer</i> , 2015, 16, 358-365.	2.6	14
81	Epigenetic Silencing of Immune-Checkpoint Receptors in Bone Marrow- Infiltrating T Cells in Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 663406.	2.8	14
82	Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Nonâ€“Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial. <i>Clinical Lung Cancer</i> , 2017, 18, 303-309.	2.6	13
83	Treatment sequence in patients with neuroendocrine tumours: a nationwide multicentre, observational analysis of the Swiss neuroendocrine tumour registry. <i>Swiss Medical Weekly</i> , 2020, 150, w20176.	1.6	11
84	Early Clinical Trial Experience with Vaccine Therapies in Nonâ€“Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2008, 9, S20-S27.	2.6	10
85	From "magic bullets" to specific cancer immunotherapy. <i>Swiss Medical Weekly</i> , 2013, 143, w13734.	1.6	10
86	LIGHT/LTÎ²R signaling regulates self-renewal and differentiation of hematopoietic and leukemia stem cells. <i>Nature Communications</i> , 2021, 12, 1065.	12.8	9
87	Neoadjuvant chemotherapy with or without preoperative irradiation in stage IIIA/N2 non-small cell lung cancer (NSCLC): A randomized phase III trial by the Swiss Group for Clinical Cancer Research (SAKK trial 16/00).. <i>Journal of Clinical Oncology</i> , 2013, 31, 7503-7503.	1.6	9
88	Chronic myelogenous leukemia maintains specific CD8⁺ T cells through IL↑7 signaling. <i>European Journal of Immunology</i> , 2010, 40, 2720-2730.	2.9	8
89	Detecting BRAF Mutations in Formalin-Fixed Melanoma: Experiences with Two State-of-the-Art Techniques. <i>Case Reports in Oncology</i> , 2012, 5, 280-289.	0.7	8
90	Chemotherapy negatively impacts the tumor immune microenvironment in NSCLC: an analysis of pre- and post-treatment biopsies in the multi-center SAKK19/09 study. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 405-415.	4.2	8

#	ARTICLE	IF	CITATIONS
91	Long term survival after trimodal therapy in malignant pleural mesothelioma. Swiss Medical Weekly, 2012, 142, w13686.	1.6	8
92	Interferons in hematopoiesis and leukemia. Oncoimmunology, 2013, 2, e24572.	4.6	6
93	Outcome of the antibody response: a question of antigen dose and distribution. Trends in Immunology, 2004, 25, 165-166.	6.8	4
94	Genetic Alterations Impact Immune Microenvironment Interactions in Follicular Lymphoma. Cancer Cell, 2020, 37, 621-622.	16.8	4
95	Complete pain relief after bevacizumab in a patient with neurofibromatosis type 2. Acta Oncologica, 2015, 54, 280-283.	1.8	2
96	T cell inhibitory mechanisms in a model of aggressive Non-Hodgkin's Lymphoma. Oncoimmunology, 2018, 7, e1365997.	4.6	2
97	Reply to M.C. Chamberlain. Journal of Clinical Oncology, 2010, 28, e696-e697.	1.6	0
98	Abstract PO-039: Radiation therapy enhances anti-tumor activity of a MET CAR T-based immunotherapy approach for glioblastoma multiforme. , 2021, , .		0
99	SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small Cell Lung Cancer " A Multicentre Single-Arm Phase II Trial. SSRN Electronic Journal, 0, , .	0.4	0
100	PD-1 Signaling on Chronic Myeloid Leukemia-Specific T Cells Results in T Cell Exhaustion and Disease Progression.. Blood, 2007, 110, 2923-2923.	1.4	0
101	The imaging substudy of the randomized ARTE trial: MRI and 18FET PET associations with overall survival benefit from bevacizumab in elderly patients with newly diagnosed IDH wildtype glioblastoma.. Journal of Clinical Oncology, 2020, 38, 2520-2520.	1.6	0